7.68
price up icon2.26%   0.17
after-market Handel nachbörslich: 7.58 -0.10 -1.30%
loading
Schlusskurs vom Vortag:
$7.51
Offen:
$7.39
24-Stunden-Volumen:
6.99M
Relative Volume:
2.26
Marktkapitalisierung:
$1.02B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-3.802
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
-7.19%
1M Leistung:
-26.08%
6M Leistung:
-50.03%
1J Leistung:
-72.51%
1-Tages-Spanne:
Value
$7.25
$7.70
1-Wochen-Bereich:
Value
$7.25
$8.415
52-Wochen-Spanne:
Value
$6.78
$29.37

10 X Genomics Inc Stock (TXG) Company Profile

Name
Firmenname
10 X Genomics Inc
Name
Telefon
(925) 401-7300
Name
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Name
Mitarbeiter
1,306
Name
Twitter
@10xgenomics
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
TXG's Discussions on Twitter

Vergleichen Sie TXG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Health Information Services icon
TXG
10 X Genomics Inc
7.68 1.02B 631.73M -239.78M -33.45M -2.02
Health Information Services icon
VEEV
Veeva Systems Inc
210.08 36.39B 2.75B 714.14M 1.09B 4.33
Health Information Services icon
DOCS
Doximity Inc
51.28 9.87B 516.85M 174.11M 217.38M 0.87
Health Information Services icon
TEM
Tempus Ai Inc
40.98 7.46B 640.44M -743.28M -206.93M -11.29
Health Information Services icon
HQY
Healthequity Inc
80.20 7.21B 1.15B 96.70M -161.99M 1.09
Health Information Services icon
WAY
Waystar Holding Corp
35.21 6.30B 906.14M -52.62M 89.62M -0.3621

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-03 Eingeleitet Leerink Partners Outperform
2024-07-22 Hochstufung Jefferies Hold → Buy
2024-07-18 Herabstufung JP Morgan Overweight → Neutral
2024-07-10 Herabstufung Deutsche Bank Buy → Hold
2024-06-27 Herabstufung Wolfe Research Outperform → Peer Perform
2024-06-25 Herabstufung Guggenheim Buy → Neutral
2024-06-03 Fortgesetzt Jefferies Hold
2024-05-01 Herabstufung TD Cowen Buy → Hold
2023-12-14 Eingeleitet Guggenheim Buy
2023-12-13 Eingeleitet Wolfe Research Outperform
2023-12-12 Hochstufung BofA Securities Underperform → Neutral
2023-07-05 Fortgesetzt JP Morgan Overweight
2023-05-10 Eingeleitet Barclays Overweight
2023-03-31 Eingeleitet Stephens Overweight
2023-02-02 Eingeleitet UBS Neutral
2022-12-14 Eingeleitet Deutsche Bank Buy
2022-08-18 Herabstufung Goldman Neutral → Sell
2022-07-25 Eingeleitet Canaccord Genuity Buy
2022-07-15 Herabstufung BofA Securities Neutral → Underperform
2022-07-15 Herabstufung William Blair Outperform → Mkt Perform
2021-10-15 Fortgesetzt Cowen Outperform
2021-09-14 Herabstufung BofA Securities Buy → Neutral
2021-03-15 Eingeleitet William Blair Outperform
2020-12-02 Eingeleitet Goldman Neutral
2020-09-09 Eingeleitet Morgan Stanley Overweight
2020-07-10 Eingeleitet Stifel Buy
2020-03-05 Eingeleitet Guggenheim Buy
2020-01-07 Eingeleitet Citigroup Buy
2019-10-07 Eingeleitet BofA/Merrill Buy
2019-10-07 Eingeleitet Cowen Outperform
2019-10-07 Eingeleitet JP Morgan Overweight
2019-09-24 Eingeleitet Evercore ISI Outperform
Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

pulisher
Apr 19, 2025

Advancing the Future of Biomarker-Driven Immunotherapy - Fierce Biotech

Apr 19, 2025
pulisher
Apr 18, 2025

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 15, 2025

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace

Apr 15, 2025
pulisher
Apr 14, 2025

BofA Securities Cuts Price Target on 10x Genomics to $12 From $16, Neutral Rating Maintained - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

10x Genomics (TXG) Price Target Reduced Amid Policy and Economic Concerns | TXG Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 11, 2025

Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump - simplywall.st

Apr 11, 2025
pulisher
Apr 11, 2025

Spatial Genomics Transcriptomics Market Is Booming Worldwide | - openPR.com

Apr 11, 2025
pulisher
Apr 10, 2025

Single-cell Omics Emerging Technologies and Markets Report - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance

Apr 10, 2025
pulisher
Apr 09, 2025

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - Yahoo Finance

Apr 09, 2025
pulisher
Apr 05, 2025

10x Genomics Reports Third Quarter 2023 Financial Results - Seeking Alpha

Apr 05, 2025
pulisher
Apr 05, 2025

10X Genomics stock hits 52-week low at $7.43 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

10X Genomics stock hits 52-week low at $7.43 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 01, 2025

IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Apr 01, 2025
pulisher
Mar 28, 2025

10X Genomics stock plunges to 52-week low of $9.27 By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

10X Genomics stock plunges to 52-week low of $9.27 - Investing.com

Mar 28, 2025
pulisher
Mar 27, 2025

We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

UPC infringement case can resume after EPO upholds 10x Genomics patent - JUVE Patent

Mar 27, 2025
pulisher
Mar 21, 2025

10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus.com

Mar 21, 2025
pulisher
Mar 20, 2025

10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha

Mar 20, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 11, 2025

Long Read Sequencing Market Top Companies Study10X Genomics, - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex

Mar 10, 2025
pulisher
Mar 09, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 08, 2025

10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Strategic Move: Healthcare Giant Zimmer Biomet Taps Communications Veteran from 10x Genomics - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK

Mar 05, 2025
pulisher
Mar 05, 2025

10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 05, 2025

Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics secures injunction against Parse Biosciences - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times

Mar 03, 2025
pulisher
Mar 02, 2025

10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io

Mar 02, 2025
pulisher
Mar 01, 2025

ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St

Feb 27, 2025
pulisher
Feb 27, 2025

Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks

Feb 27, 2025
pulisher
Feb 26, 2025

Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat

Feb 26, 2025
pulisher
Feb 26, 2025

10x genomics’ president sells $50,602 in stock - Investing.com India

Feb 26, 2025

Finanzdaten der 10 X Genomics Inc-Aktie (TXG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$19.32
price down icon 0.05%
$26.19
price up icon 1.71%
$14.47
price up icon 2.26%
$22.71
price down icon 4.10%
$15.62
price down icon 5.90%
health_information_services WAY
$35.21
price down icon 3.40%
Kapitalisierung:     |  Volumen (24h):